David Sinclair· PhD
Fertilization outcomes improved, with higher numbers of normally fertilized 2PN embryos (3.75 ± 2.91vs. 5.75 ± 3.45; p = 0.018)
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Fertilization outcomes improved, with higher numbers of normally fertilized 2PN embryos (3.75 ± 2.91vs. 5.75 ± 3.45; p = 0.018)
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Improvements were observed across both POSEIDON Group 3 (<35 years) and Group 4 (≥35 years)
Following NAD⁺ therapy, there was a significant increase in the number of mature metaphase II (MII) oocytes retrieved (4 .06 ± 3.04 vs. 6.06 ± 3.51; p = 0.024).
Embryo quality showed the most pronounced improvement, with a marked increase in Grade A embryos (1.62 ± 1.11vs. 4 .31± 2.05; p < 0.001) and overall good-quality embryos (Grade A + B) (2.06 ± 1.23 vs. 4 .62 ± 1.45; p < 0.001).
when we give nad to quite neatly precursors to eggs in vivo the eggs come out healthier more numerous and are much better at allowing for fertilization and healthy offspring